Study Finds Health & Financial Benefits in AxSpA Treat-To-Target Strategy

Thomas R. Collins is a freelance writer living in South Florida.

References

1. Molto A, Lopez-Medina C, Van den Bosch F, et al. Cluster-randomized pragmatic clinical trial evaluating the potential benefit of a tight-control and treat-to-target strategy in axial spondyloarthritis: The results of the TICOSPA trial. Presented 2020 Jun 4 at the European e-Congress of Rheumatology.
2. Che H, Etcheto A, Dernis E, et al. Evaluation of collected outcome measures in axial spondyloarthritis in daily-care rheumatology settings: The experience of the RHEVER network. Clin Exp Rheumatol. 2015 Nov–Dec;33(6):851–857.
3. Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014 Aug;73(8):1455–1461.
4. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009 Jan;68(1):18–24.